APA (7th ed.) Citation

Ferrarotto, R., Metcalf, R., Rodriguez, C. P., Muzaffar, J., Even, C., Perez, C. A., . . . Ho, A. L. (2022). Results of ACCURACY: A phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut). Journal of clinical oncology, 40(16_suppl), 6046. https://doi.org/10.1200/JCO.2022.40.16_suppl.6046

Chicago Style (17th ed.) Citation

Ferrarotto, Renata, et al. "Results of ACCURACY: A Phase 2 Trial of AL101, a Selective Gamma Secretase Inhibitor, in Subjects with Recurrent/metastatic (R/M) Adenoid Cystic Carcinoma (ACC) Harboring Notch Activating Mutations (Notchmut)." Journal of Clinical Oncology 40, no. 16_suppl (2022): 6046. https://doi.org/10.1200/JCO.2022.40.16_suppl.6046.

MLA (9th ed.) Citation

Ferrarotto, Renata, et al. "Results of ACCURACY: A Phase 2 Trial of AL101, a Selective Gamma Secretase Inhibitor, in Subjects with Recurrent/metastatic (R/M) Adenoid Cystic Carcinoma (ACC) Harboring Notch Activating Mutations (Notchmut)." Journal of Clinical Oncology, vol. 40, no. 16_suppl, 2022, p. 6046, https://doi.org/10.1200/JCO.2022.40.16_suppl.6046.